A clinical study to assess whether there is a difference in outcomes in patients receiving either the PFC or the Attune knee replacement

ISRCTN ISRCTN10345709
DOI https://doi.org/10.1186/ISRCTN10345709
IRAS number 160047
Secondary identifying numbers IRAS 160047
Submission date
04/10/2020
Registration date
06/10/2020
Last edited
07/01/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Total knee replacement (arthroplasty) is usually a successful procedure with excellent outcomes although 15% of patients report they are dissatisfied. Design differences between replacement knee parts (prostheses) continue to be developed in an effort to improve these outcomes. The aim of this study is to evaluate the effect of these new design features on the outcomes following total knee arthroplasty.

Who can participate?
Patients aged 22 to 90 years old, with osteoarthritis of the knee requiring replacement

What does the study involve?
Participants will be randomly allocated to undergo a total knee replacement with either the DePuy Synthes ATTUNETM or the DePuy Synthes PFC SigmaTM cruciate-retaining systems. Patients will be followed up for 1 year.

What are the possible benefits and risks of participating?
The possible benefits include active participation in a trial to improve patient outcomes, and playing an important part in improving patient outcomes whilst not compromising their own outcome.
The new implant may not necessarily improve outcomes, but there are several studies highlighting that the newer implant has at least equivalent outcomes and is not inferior which maintains patient safety. The longer-term outcomes are yet unknown - i.e. the longevity of implant, and the need for revision at an earlier stage.

Where is the study run from?
Wrightington Hospital (UK)

When is the study starting and how long is it expected to run for?
May 2014 to August 2017

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Sunil Panchani
sunil.panchani@wwl.nhs.uk

Contact information

Mr Sunil Panchani
Scientific

Wrightington Hospital
Wigan
WN6 9EP
United Kingdom

ORCiD logoORCID ID 0000-0001-7297-9412
Phone +44 (0)1257 258251
Email sunil.panchani@wwl.nhs.uk

Study information

Study designSingle (patient) blinded single centre randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleEarly functional outcomes after evolutionary total knee arthroplasty: a randomized controlled trial
Study objectivesThis study investigates whether or not there is a difference between the PFC or the Attune Total Knee replacement systems in terms of functional and clinical outcomes.
Ethics approval(s)Approved 10/11/2014, NRES Committee North West - Greater Manchester South (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8063; gmsouth.rec@hra.nhs.uk), REC ref: 14/NW/1330
Health condition(s) or problem(s) studiedOsteoarthritis of knee
InterventionThe study is designed as a single-blinded randomized controlled trial with patients blinded to their treatment arm. Subjects will remain blinded as to their treatment arm for the duration of the trial period which will be 1 year for each subject. The patient population will comprise patients being referred to or currently under review for symptomatic knee osteoarthritis at Wrightington Hospital, United Kingdom.

Patients will be primarily recruited and consented during the clinic consultation. Enrolment and consent to the trial will only be performed by researchers with Good Clinical Practice (GCP) certification. Consent forms and patient information sheets have been devised using departmental guidance and protocols.

Procedure
Patients undergo a total knee replacement with either the DePuy Synthes ATTUNETM or the DePuy Synthes PFC SigmaTM cruciate-retaining system

Data collection
Both demographic and clinical data will be recorded throughout the trial period. Demographic data will include age, sex, height, weight, body mass index as well as co-morbidities. Clinical data will include implant sizes, wound closure methods, tourniquet time, ASA grade, Hospital Length of Stay, Pre and post-operative Haemoglobin and complications including but not limited to infection, deep vein thrombosis and further surgery to the operated or non operated limb within the trial period for any reason will be recorded.

Clinical and Functional Outcome measures
The outcomes of interest comprise general and disease-specific patient-reported outcome measures (PROMs). Disease-specific scores include the Oxford Knee Score (OKS)7, the Oxford Knee Score Activity and Participation Questionnaire (OKS-APQ)8 and the Patient Knee Implant Performance score (PKIP)9. The SF-3610 and EQ5D – 5L11 will also be completed as generic health measures.
The pre- and post-operative range of movement (ROM) as measured with a goniometer will also be assessed together with Visual Analogue Pain Scores (VAS).

Trial packs comprising a pre-operative pack, a 6-week post-operative pack, a 12-week post-operative pack and a 52-week post-operative pack will be devised comprising the relevant outcome measures to allow ease of completion for the subjects.

Randomization
Patients will be randomized using sealed envelopes based on lists prepared in advance of the first patient being randomised. Randomisation lists shall be produced by the trial statistician via randomly permuted blocks using the 'ralloc’ command within the statistical package Stata R. No stratification factors are to be included in the study.

The primary endpoint is the difference between pre-surgery and 6 weeks, 3 months and 1-year measurements of the Oxford Knee Score.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)PFC and ATTUNE Total Knee Replacement systems - DePuy Synthes
Primary outcome measureKnee function measured using the Oxford Knee Score at baseline, 6 weeks, 3 months and 1 year
Secondary outcome measures1. Knee function measured using the OKS-APQ Questionnaire at baseline, 6 weeks, 3 months and 1 year
2. Knee function measured using the PKIP Questionnaire at baseline, 6 weeks, 3 months and 1 year
3. General health measured using the SF-36 Questionnaire at baseline and 1 year
4. Quality of life measured using the EQ5D-5L Questionnaire at baseline, 6 weeks, 3 months and 1 year
5. Pain measured using VAS Questionnaire at baseline, 6 weeks, 3 months and 1 year
6. Range of movement measured using a Goniometer at baseline, 6 weeks, 3 months and 1 year
Overall study start date01/05/2014
Completion date01/08/2017

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants150
Total final enrolment150
Key inclusion criteria1. 22 to 90 years old inclusive
2. A diagnosis of non-inflammatory osteoarthritis of the knee
3. Primary varus osteoarthritic deformity
4. Stable collateral ligaments at the time of pre-operative clinical examination
5. Patient is a candidate for routine primary knee arthroplasty (cruciate retaining) in line with manufacturer guidelines
6. Subject is able to give consent to the procedure
Key exclusion criteria1. A patient with a diagnosis of inflammatory osteoarthritis
2. Severe bone defects or deformity which will require augmentation with bone graft or augmented prosthesis or a constrained device
3. Valgus osteoarthritis
4. Previous patellectomy
5. Patient has a contralateral TKR which is a PFCTM or ATTUNETM implant
6. Patient has a poorly functioning or symptomatic contra-or ipsilateral total hip replacement
7. Previous lower limb amputation on either limb
8. Previous fractures, osteotomy or surgery to the knee which required metal implantation and/or ligament reconstruction
9. Neurogenic cause for arthritis in the knee or associated neurological symptoms in lower limb referred from spine
Date of first enrolment01/12/2014
Date of final enrolment01/08/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Wrightington Hospital
Appley Bridge
Hall Lane
Wigan
WN6 9EP
United Kingdom

Sponsor information

Wrightington Hospital
Hospital/treatment centre

Hall Lane
Wigan
WN6 9EP
England
United Kingdom

Phone +44 (0)1942 244 000
Email Tim.Board@wwl.nhs.uk
Website http://www.wwl.nhs.uk/hospitals/wrightington/default.aspx
ROR logo "ROR" https://ror.org/00y112q62

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date01/04/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
JBJS - article
BOA, BASK - International Presentations
IPD sharing planThe datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. The data is stored in a secure password-protected file on a Hospital secured drive and only the research team have access to this.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 29/08/2015 06/10/2020 Yes No
Results article 28/07/2021 07/01/2022 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

07/01/2022: Publication reference added.
06/10/2020: Trial's existence confirmed by NRES Committee North West - Greater Manchester South.